Logo image of BBIO

BRIDGEBIO PHARMA INC (BBIO) Stock Fundamental Analysis

NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD

33.34  +0.37 (+1.12%)

After market: 33.64 +0.3 (+0.9%)

Fundamental Rating

3

Taking everything into account, BBIO scores 3 out of 10 in our fundamental rating. BBIO was compared to 562 industry peers in the Biotechnology industry. BBIO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BBIO has reported negative net income.
In the past year BBIO has reported a negative cash flow from operations.
BBIO had negative earnings in each of the past 5 years.
In the past 5 years BBIO always reported negative operating cash flow.
BBIO Yearly Net Income VS EBIT VS OCF VS FCFBBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -75.76%, BBIO is not doing good in the industry: 67.08% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -75.76%
ROE N/A
ROIC N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBIO Yearly ROA, ROE, ROICBBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

BBIO's Gross Margin of 95.35% is amongst the best of the industry. BBIO outperforms 95.02% of its industry peers.
In the last couple of years the Gross Margin of BBIO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
BBIO Yearly Profit, Operating, Gross MarginsBBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BBIO has been increased compared to 1 year ago.
Compared to 5 years ago, BBIO has more shares outstanding
BBIO has a better debt/assets ratio than last year.
BBIO Yearly Shares OutstandingBBIO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BBIO Yearly Total Debt VS Total AssetsBBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -5.36, we must say that BBIO is in the distress zone and has some risk of bankruptcy.
BBIO has a Altman-Z score of -5.36. This is in the lower half of the industry: BBIO underperforms 60.50% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.36
ROIC/WACCN/A
WACC9.55%
BBIO Yearly LT Debt VS Equity VS FCFBBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 4.57 indicates that BBIO has no problem at all paying its short term obligations.
BBIO's Current ratio of 4.57 is in line compared to the rest of the industry. BBIO outperforms 51.25% of its industry peers.
A Quick Ratio of 4.54 indicates that BBIO has no problem at all paying its short term obligations.
BBIO has a Quick ratio (4.54) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.57
Quick Ratio 4.54
BBIO Yearly Current Assets VS Current LiabilitesBBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BBIO have decreased strongly by -17.08% in the last year.
The Revenue for BBIO has decreased by -41.71% in the past year. This is quite bad
Measured over the past years, BBIO shows a very strong growth in Revenue. The Revenue has been growing by 40.48% on average per year.
EPS 1Y (TTM)-17.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-340%
Revenue 1Y (TTM)-41.71%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%-44.76%

3.2 Future

BBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.33% yearly.
The Revenue is expected to grow by 59.17% on average over the next years. This is a very strong growth
EPS Next Y-4.53%
EPS Next 2Y15.66%
EPS Next 3Y26.28%
EPS Next 5Y24.33%
Revenue Next Year87.39%
Revenue Next 2Y71.56%
Revenue Next 3Y76.87%
Revenue Next 5Y59.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BBIO. In the last year negative earnings were reported.
Also next year BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBIO Price Earnings VS Forward Price EarningsBBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBIO Per share dataBBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

BBIO's earnings are expected to grow with 26.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.66%
EPS Next 3Y26.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (5/23/2025, 9:15:05 PM)

After market: 33.64 +0.3 (+0.9%)

33.34

+0.37 (+1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners78.13%
Inst Owner Change5.06%
Ins Owners2.41%
Ins Owner Change-128.18%
Market Cap6.33B
Analysts81.67
Price Target60.44 (81.28%)
Short Float %14.2%
Short Ratio7.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.41%
Min EPS beat(2)-21.38%
Max EPS beat(2)6.56%
EPS beat(4)2
Avg EPS beat(4)9.76%
Min EPS beat(4)-21.38%
Max EPS beat(4)64.07%
EPS beat(8)3
Avg EPS beat(8)8.11%
EPS beat(12)5
Avg EPS beat(12)12.33%
EPS beat(16)6
Avg EPS beat(16)9.04%
Revenue beat(2)2
Avg Revenue beat(2)75.17%
Min Revenue beat(2)65.74%
Max Revenue beat(2)84.61%
Revenue beat(4)2
Avg Revenue beat(4)20.27%
Min Revenue beat(4)-40.46%
Max Revenue beat(4)84.61%
Revenue beat(8)3
Avg Revenue beat(8)167.07%
Revenue beat(12)4
Avg Revenue beat(12)123.7%
Revenue beat(16)5
Avg Revenue beat(16)83.96%
PT rev (1m)6.89%
PT rev (3m)14.96%
EPS NQ rev (1m)17.27%
EPS NQ rev (3m)20.58%
EPS NY rev (1m)15.64%
EPS NY rev (3m)13.48%
Revenue NQ rev (1m)70.28%
Revenue NQ rev (3m)197.92%
Revenue NY rev (1m)66.36%
Revenue NY rev (3m)123.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 49.68
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.77
EYN/A
EPS(NY)-2.05
Fwd EYN/A
FCF(TTM)-2.68
FCFYN/A
OCF(TTM)-2.64
OCFYN/A
SpS0.67
BVpS-8.68
TBVpS-8.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.35%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.36%
Cap/Sales 7.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.57
Quick Ratio 4.54
Altman-Z -5.36
F-Score2
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)86.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)8.73%
Cap/Sales(5y)27.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-340%
EPS Next Y-4.53%
EPS Next 2Y15.66%
EPS Next 3Y26.28%
EPS Next 5Y24.33%
Revenue 1Y (TTM)-41.71%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%-44.76%
Revenue Next Year87.39%
Revenue Next 2Y71.56%
Revenue Next 3Y76.87%
Revenue Next 5Y59.17%
EBIT growth 1Y-44.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.1%
EBIT Next 3Y30.23%
EBIT Next 5Y20.69%
FCF growth 1Y-24.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.12%
OCF growth 3YN/A
OCF growth 5YN/A